Vasopressin (or Argipressin)

Therapeutic

For the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding,in abdominal roentgenography to dispel interfering gas shadows, and for the prevention and treatment of postoperative abdominal distention.

Structural features

SMILES

C1C[C@H](N(C1)C(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N

Sequence

CYFQNCPRG-NH2

Molar mass

1084.24 g/mol

Constitutional members:

9

Natural amino acids

9

D-Amino acids

0

N-terminus

H

C-terminus

NH2

Cyclic

yes

Members/cycle

6

Bond to form cycle

side chain-to-side chain (disulfide)

Lipidation

no

Glycosylation

no

Route of administration

IM, SC, IV, NASAL

Terminal half-life

10-20 min

Protein binding

0.01

Absorption and Bioavailability

Vasopressin has almost 0% oral bioavailability

References